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To the Editor,
Voriconazole (VRC) is a second-generation triazole 
licensed to treat patients with invasive aspergillosis, 
invasive candiadiasis caused by Candida species with 
reduced susceptibility to fluconazole, and serious infec-
tions caused by Scedosporium and Fusarium species [1, 2]. 
Recently, prophylaxis of invasive fungal infections (IFIs) 
in high risk allogeneic hematopoietic stem cell transplant 
recipients was added as a new indication for VRC [3]. 
According to the British Society for Medical Microbiology 
(BSMM), trough concentrations  > 1 mg/L and  < 4–6 mg/L 
are required to maximize efficacy and to minimize drug-
related toxicity [4].
In patients treated for IFIs with the recommended 
oral/intravenous VRC dosage regimen, large inter- and 
intra-individual variability has been found in VRC trough 
plasma concentrations, ranging from undetectable con-
centrations to 11 mg/L [5]. Oral bioavailability is a major 
determinant of variability of VRC plasma concentrations 
[6]. In healthy individuals, oral bioavailability is reported 
to be high, approximately 96%, when administered in 
a fasting state (1  h before/after meal) [2]. However, in 
patients, oral bioavailability might be much lower, as 
these patients are frequently suffering from gastro-intes-
tinal complications [6, 7]. Other factors that contribute 
to the variability in VRC plasma concentrations are the 
Michaelis-Menten (non-linear) pharmacokinetics of VRC, 
polymorphisms of the gene encoding the CYP2C19 enzyme, 
drug-drug interactions, liver disease and age [4]. The large 
variability in VRC plasma concentrations together with the 
narrow therapeutic window for treating patients with IFIs, 
makes individualized dosing adjustments based on thera-
peutic drug monitoring (TDM) of VRC necessary to opti-
mize therapeutic response and to minimize the probability 
of neurotoxicity [6]. According to the BSMM, VRC plasma 
concentrations should be measured in the first 5 days of 
therapy and regularly thereafter [4].
In Table 1, an overview is given of the analytical 
methods that are suitable for measuring VRC in plasma, 
including bioassays [8–11], HPLC [12–19] and LC-MSMS [20–
29] methods. Currently, chromatographic methods are pre-
dominantly used, as can also be derived from proficiency 
testing results [30]. These techniques are accurate, precise 
and allow the simultaneous analysis of multiple anti-
fungal drugs. However, these methods also include some 
disadvantages, such as the limited availability of chromato-
graphic instruments in the core clinical laboratory, the need 
for skilled laboratory technicians, the use of (sometimes) 
time consuming sample preparation steps and the need 
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Table 1 Characteristics of the analytical methods used for measurement of VRC plasma concentrations.
 
 
Current methods  
 
New method
Bioassay   HPLC/UPLC-UV/
fluorescence detection
  LC-MS(MS) ARKTM immuno-assay
Sample volume (plasma)  10–25 μL   100–500 μL   5–200 μL   100 μL
Sensitivity/LOQ   0.25–0.5 mg/L   0.03–0.5 mg/L   0.002–0.1 mg/L   0.4 mg/L
TAT   20–24 h   1–3 h    < 30 min   5 min
Use   Clinical practice (TDM)   Clinical practice (TDM)   Clinical practice (TDM)   Clinical practice (TDM)
      Pharmacokinetic 
studies
 
Advantages  
 
 
 
 – Inexpensive
 – No expertise needed
 
 
 
 
 –  Less expensive 
equipment than 
LC-MS
 –  Possibility of 
simultaneous 
analysis of multiple 
drugs
 
 
 
 –  Minimal sample 
preparation
 –  Small sample 
volume
 
 
 
 –  No need for specific 
equipment/For use 
on random access 
chemistry analyzers
 –  No need for analysis 
in batch
 –  Very sensitive and 
specific
 
Disadvantages  
 
 
 
 –  Unsuitable for 
patients receiving 
antifungal 
combination therapy
 –  Lower precision and 
accuracy
 –  Lack of 
standardization
 
 
 
 –  Large sample 
volume needed to 
ensure sensitivity
 
 
 –  Expensive 
equipment
 –  Not widely available
 
 
 
 
 –  Requirement 
of  ± 120 requests/
month (kit stability)
 –  Subject to 
interference from 
multiple substances
 –  Analysis in batch 
with calibration and 
controls in each 
batch
   –  Expertise needed to 
perform analysis
References   [8–11]   [12–19], this study   [20–29]  
LOQ, limit of quantification; TAT, turn-around-time ( = plasma pretreatment+analysis time).
Table 2 Within-run imprecision, between-run imprecision and bias of the ARKTM VRC immunoassay on the c502 module of the Cobas 8000 
analyzer.
Quality 
control
  Target concentration, 
mg/L
 
 
Within-run imprecision 
(n = 21)
 
 
Between-run imprecision 
(n = 40, pool: n = 22)
  Bias 
(n = 40)
Mean   SD   CV Mean   SD   CV
Low   1.5   1.62   0.08   5.03%   1.58   0.11   6.77%   5.33%
Mid   5.0   4.93   0.19   3.88%   5.05   0.31   6.14%   1.00%
High   10.0   9.74   0.48   4.96%   10.17   0.68   6.72%   1.70%
Plasma pool     0.43   0.03   7.16%   3.11   0.16   5.06%  
CV, coefficient of variation.
to work in batch with repetitive calibrations, resulting in a 
long turn-around-time. Consequently, TDM-assisted VRC 
dose adjustment with chromatographic techniques is very 
challenging. The implementation of a fast and reliable VRC 
immunoassay on an open-access chemistry analyzer could 
significantly improve VRC therapeutic target achievement, 
and minimize the drug-related adverse effects.
Recently, ARKTM Diagnostics, Inc. (Fremont, CA, USA) 
has introduced a VRC homogeneous enzyme immunoas-
say (Test principle: see Supplemental Material), for use 
on random access chemistry analyzers. In this study, we 
evaluated an investigational reagent lot (not approved 
for routine clinical application) of this assay in an open 
channel on the c502 module of the Cobas 8000 analyzer 
(Roche Diagnostics, Mannheim, Germany) in the core 
laboratory of Ghent University Hospital. The application 
protocol was obtained from ARKTM Diagnostics (Supple-
mental Material, Table 1). One assay kit contains reagents 
for 210 tests and analysis time on the c502 instrument is 
5 min. Full calibration and quality control evaluation were 
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Figure 1 Passing-Bablok regression (A and C) and Bland-Altman plot (B) for comparison between ARKTM VRC immunoassay and UPLC-PDA 
(n = 113, A and B) and between ARKTM Lot 1 (investigational lot) and Lot 2 (lot certified for clinical application) (n = 20).
Individual observations are represented as triangles. (A and B) Seven samples were excluded from the analysis because they had a VRC 
concentration below the LOQ. (A) The identity line is dashed. The continuous line shows the fitted regression line. Regression equation: 
y = 0.098+1.052x. (B) Horizontal lines are drawn at the mean difference (continuous line), and at the limits of agreement (dashed lines), 
which are defined as the mean difference plus and minus 1.96 times the standard deviation (SD) of the differences. (C) The identity line is 
dashed. The continuous line shows the fitted regression line. Regression equation: y = 0.173+0.922x. Confidence intervals (CI) for slope and 
intercept are indicated.
performed using the ready-to-use calibrators (6  points: 
0.0, 1.0, 2.0, 4.0, 8.0 and 16.0 mg/L) and quality controls 
(1.5, 5.0 and 10.0 mg/L).
Within-run (n = 21), between-run imprecision and 
accuracy (n = 40, 25 days) were evaluated using quality 
control material and a plasma pool and were all found 
acceptable ( < 7% at all tested concentrations, Table 2).
We evaluated the linearity of the VRC assay according 
to NCCLS guideline EP6-A. We prepared a dilution series 
covering the range 0.5–16.2 mg/L, as described in the 
Supplemental Material. As the deviation from linearity 
is considered not clinically important ( < 10%), linearity 
is accepted within the tested range (Supplemental Mate-
rial, Figure 1). Based on our experiments according to 
NCCLS EP17-A2 specifications, we obtained a functional 
sensitivity of 0.4 mg/L (CV 10%) (Supplemental Mate-
rial, Figure 2). Recovery was tested by diluting (1:2, 1:4, 
1:8 and 1:16) a native human plasma with a VRC concen-
tration of 11.1 mg/L, where the result of the undiluted 
plasma was taken as 100% recovery. Mean recoveries of 
duplicate measurements of the diluted plasmas ranged 
between 99% and 107%.
Specificity was tested using samples provided by 
ARKTM Diagnostics containing 3 mg/L VRC in combination 
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with the potential cross-reacting compounds flucona-
zole (30 mg/L), itraconazole (20 mg/L), posaconazole 
(20  mg/L) or the inactive N-oxide metabolite of VRC 
(10  mg/L). No interferences were found (Supplemental 
Material, Table 2).
During a period of 4 months, a method comparison 
was performed using 113 routine blood samples from 
patients receiving VRC. The VRC immunoassay was com-
pared with the routinely used ultra-high performance 
liquid chromatography method with photodiode array 
detection (UPLC-PDA) carried out at the General Hospital 
St-Lucas, Ghent (Test principle: see Supplemental Mate-
rial). Patient care relied solely on the UPLC-PDA method 
determination of VRC and the study was approved by the 
Ethics Committee of Ghent University Hospital (registra-
tion number B670201319303). Blood was drawn prior to 
administration of the next VRC dose and lithium heparin 
tubes without gel separator (Venosafe, Terumo Europe, 
Belgium) were used. As VRC is very stable in serum/
plasma (at least 7 days at room temperature, and 1 month 
at –20 °C), and is not affected by multiple freeze-thaw 
cycles (own unpublished data and [14]), fresh and frozen 
plasma samples were used. Results were analyzed using 
MedCalc Software (Mariakerke, Belgium). Seven samples, 
with results  < 0.5 mg/L on both methods, were excluded 
from further analysis. Method comparison of the VRC 
immunoassay and UPLC-PDA showed a significant linear 
correlation (Pearson’s r: 0.978, p < 0.0001). Passing-Bablok 
regression showed an intercept of 0.098 (95% CI –0.025 to 
0.250) and slope of 1.052 (95% CI 0.996–1.105), with a sub-
stantial agreement between both methods, as indicated by 
a concordance correlation coefficient (CCC) of 0.96. Bland-
Altman plot revealed a small systematic error of 0.29 mg/L 
between both methods (Figure 1A and B).
We also tested 12 control samples from United 
Kingdom National External Quality Assessment Service 
(UK NEQAS) with All Laboratory Trimmed Mean (ALTM) 
concentrations ranging from 0.37 to 9.03 mg/L (11/12 
samples within measuring range). Median recovery of 
the UK NEQAS samples within the measuring range was 
101% (recovery range 92%–117%). Our results did not 
significantly differ from the ALTM, as determined by the 
Wilcoxon paired-sample test (p = 0.42). Lot-to-lot consist-
ency was explored by re-measurement of plasma samples 
(n = 20), using the first VRC reagent lot and calibrator lot, 
approved for routine clinical application. Passing-Bablok 
regression showed no significant systematic or propor-
tional differences between both lots (Figure 1C). Analy-
sis of three UK NEQAS (n = 3, ALTM concentrations 0.98, 
1.59 and 8.16 mg/L) with the new reagent/calibrator lot 
resulted in a recovery of 99%–105%.
As the kit is containing 210 tests, reagent stability 
might be a point of concern for laboratories that have 
only a limited number of VRC requests. In our experience, 
the assay should be recalibrated on a weekly basis and 
kit stability on board of the analyzer is approximately 1 
month.
This is the first study showing results of the first VRC 
immunoassay. An advantage of this fast and ready to use 
assay is the possibility to be used on random access ana-
lyzers in the core laboratory. Hence, this test can be per-
formed on a 24/7 basis, allowing rapid adaptation of the 
dosing scheme of the patient under VRC therapy. Substan-
tial agreement was found between the results of this new 
immunoassay and a validated UPLC-PDA assay, as well 
as an independent external assessment. In conclusion, 
the ARKTM VRC immunoassay proved to be acceptable for 
implementation in daily practice.
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